Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexrazoxane Hydrochloride

FDA-approved product (injectable, injection), marketed as Dexrazoxane Hydrochloride, Totect, Zinecard.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Dexrazoxane Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Cardiomyopathy
  • Extravasation of Diagnostic and Therapeutic Materials

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Dexrazoxane Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexrazoxane Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexrazoxane Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

    NCT00410488 · start 2006-12

    Registered record
    Registry ID
    NCT00410488
    Conditions
    Sarcoma; Nausea; Vomiting
    Interventions
    Palonosetron - Single Dose; Palonosetron - Triple Dose; Adriamycin; Ifosfamide chemotherapy (AI); Zinecard; Mesna; Vincristine; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-12
    Completion
    2011-06
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Nausea; Vomiting
    InterventionPalonosetron - Single Dose; Palonosetron - Triple Dose; Adriamycin; Ifosfamide chemotherapy (AI) +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

    NCT00334867 · start 2005-12

    Registered record
    Registry ID
    NCT00334867
    Conditions
    Sarcoma
    Interventions
    cyclophosphamide; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; ifosfamide; topotecan hydrochloride; vincristine sulfate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventioncyclophosphamide; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide +5 more
    PhasePhase 3
    Registry statusWithdrawn

  • 05-001: Treatment of Acute Lymphoblastic Leukemia in Children

    NCT00400946 · start 2005-04

    Registered record
    Registry ID
    NCT00400946
    Conditions
    Drug/Agent Toxicity by Tissue/Organ; Leukemia
    Interventions
    asparaginase; cyclophosphamide; cytarabine; dexamethasone; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; mercaptopurine; methotrexate; methylprednisolone; pegaspargase; prednisolone; therapeutic hydrocortisone; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2019-06
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug/Agent Toxicity by Tissue/Organ; Leukemia
    Interventionasparaginase; cyclophosphamide; cytarabine; dexamethasone +12 more
    PhasePhase 3
    Registry statusCompleted

  • Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

    NCT00077285 · start 2003-10

    Registered record
    Registry ID
    NCT00077285
    Conditions
    Sarcoma
    Interventions
    filgrastim; carboplatin; cyclophosphamide; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; ifosfamide; irinotecan hydrochloride; vincristine sulfate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2003-10
    Completion
    2027-10
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventionfilgrastim; carboplatin; cyclophosphamide; dexrazoxane hydrochloride +7 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

    NCT00039481 · start 2002-11

    Registered record
    Registry ID
    NCT00039481
    Conditions
    Cardiac Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    oblimersen sodium; dexrazoxane hydrochloride; doxorubicin hydrochloride; cyclophosphamide; filgrastim; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-11
    Completion
    Not recorded
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventionoblimersen sodium; dexrazoxane hydrochloride; doxorubicin hydrochloride; cyclophosphamide +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

    NCT00548704 · start 2002-04

    Registered record
    Registry ID
    NCT00548704
    Conditions
    Extravasation
    Interventions
    Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2005-08
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtravasation
    InterventionDexrazoxane
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

    NCT00544778 · start 2001-08

    Registered record
    Registry ID
    NCT00544778
    Conditions
    Sarcoma
    Interventions
    filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride; ifosfamide; irinotecan hydrochloride; protein expression analysis; immunoenzyme technique; adjuvant therapy; conventional surgery; neoadjuvant therapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2001-08
    Completion
    Not recorded
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventionfilgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride; ifosfamide +7 more
    PhasePhase 2
    Registry statusTerminated

  • Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

    NCT00548561 · start 2001-06

    Registered record
    Registry ID
    NCT00548561
    Conditions
    Anthracycline Extravasation
    Interventions
    Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    2003-07
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnthracycline Extravasation
    InterventionDexrazoxane
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

    NCT00016276 · start 2001-05

    Registered record
    Registry ID
    NCT00016276
    Conditions
    Cardiac Toxicity; Inflammatory Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer
    Interventions
    dexrazoxane hydrochloride; doxorubicin hydrochloride; cyclophosphamide; paclitaxel; trastuzumab; therapeutic conventional surgery; radiation therapy; tamoxifen citrate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2001-05
    Completion
    Not recorded
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Inflammatory Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer +1 more
    Interventiondexrazoxane hydrochloride; doxorubicin hydrochloride; cyclophosphamide; paclitaxel +5 more
    PhasePhase 3
    Registry statusTerminated

  • Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors

    NCT00550901 · start 2001-02

    Registered record
    Registry ID
    NCT00550901
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    cisplatin; dexrazoxane hydrochloride; high performance liquid chromatography; laboratory biomarker analysis; mass spectrometry; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-02
    Completion
    2007-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventioncisplatin; dexrazoxane hydrochloride; high performance liquid chromatography; laboratory biomarker analysis +2 more
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Acute Lymphoblastic Leukemia in Children

    NCT00165178 · start 2000-09

    Registered record
    Registry ID
    NCT00165178
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    prednisone; dexamethasone; doxorubicin; E. coli asparaginase; vincristine; methotrexate; Leucovorin; Asparaginase; cytarabine; Methotrexate/Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-09
    Completion
    2011-05
    Enrolment
    498

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    Interventionprednisone; dexamethasone; doxorubicin; E. coli asparaginase +6 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

    NCT00019864 · start 2000-03

    Registered record
    Registry ID
    NCT00019864
    Conditions
    Cardiac Toxicity; Sarcoma
    Interventions
    filgrastim; cisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride; leucovorin calcium; methotrexate; adjuvant therapy; conventional surgery; neoadjuvant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2000-03
    Completion
    2011-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Sarcoma
    Interventionfilgrastim; cisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride +5 more
    PhasePhase 2
    Registry statusTerminated

  • Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

    NCT00003937 · start 1999-09

    Registered record
    Registry ID
    NCT00003937
    Conditions
    Cardiac Toxicity; Sarcoma
    Interventions
    cisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; ifosfamide; methotrexate; conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-09
    Completion
    2008-06
    Enrolment
    253

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Sarcoma
    Interventioncisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide +3 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

    NCT00003667 · start 1998-09

    Registered record
    Registry ID
    NCT00003667
    Conditions
    Sarcoma
    Interventions
    cyclophosphamide; dexrazoxane hydrochloride; disaccharide tripeptide glycerol dipalmitoyl; doxorubicin hydrochloride; vincristine sulfate; surgical procedure; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-09
    Completion
    2000-08
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventioncyclophosphamide; dexrazoxane hydrochloride; disaccharide tripeptide glycerol dipalmitoyl; doxorubicin hydrochloride +3 more
    PhasePhase 2
    Registry statusCompleted

  • Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

    NCT00038142 · start 1997-11

    Registered record
    Registry ID
    NCT00038142
    Conditions
    Ewing's Sarcoma
    Interventions
    Vincristine; Doxorubicin; Cyclophosphamide; Dexrazoxane; ImmTher
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    1997-11
    Completion
    2016-03
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing's Sarcoma
    InterventionVincristine; Doxorubicin; Cyclophosphamide; Dexrazoxane +1 more
    PhasePhase 2
    Registry statusTerminated